Clinical Resistance to Alkylators

Status and Perspective
  • Brian Leyland-Jones
Part of the Cancer Drug Discovery and Development book series (CDD&D)


Alkylating agents have been used in the treatment of cancer for over 50 yr, with the nitrogen mustard alkylating agent mechlorethamine being one of the first antitumor drug used in clinical practice half a century ago. These compounds can bind to a variety of cellular structures such as membranes, RNA, proteins, and DNA. It is, however, the ability to form DNA interstrand crosslinks that appears to be the most important event with regard to their antitumor activity. In addition to the nitrogen mustard agents (melphalan, chlorambucil, cyclophosphamide, and ifosfamide), the platinum drugs (cisplatin, carboplatin, and oxaliplatin) have become some of the most widely used cytotoxic anticancer agents.


Ovarian Cancer Chronic Lymphocytic Leukemia Resistant Cell Line Advanced Ovarian Cancer Nitrogen Mustard 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lebwohl D, Canetta R. Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. Eur J Cancer 1998;34:1522–1534.PubMedCrossRefGoogle Scholar
  2. 2.
    Giaccone G. Clinical perspective on platinum resistance. Drugs 2000;59(Suppl 4):9–17.PubMedCrossRefGoogle Scholar
  3. 3.
    Foon KA, Rai KR, Gale RP. Chronic lymphocytic leukemia: new insights into biology and therapy. Ann Intern Med 1990;113:525–539.PubMedGoogle Scholar
  4. 4.
    Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748–1756.PubMedGoogle Scholar
  5. 5.
    Alberts DS, Green S, Hannigan EV, et al. Improved therapeutic index of carboplatin plus cyclophosphamide vs cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages 3 and 4 ovarian cancer. J Clin Oncol 1992;10:706–717.PubMedGoogle Scholar
  6. 6.
    Evans BD, Raju KS, Calvert AH, et al. Phase II study of JM8, a new platinum analog, in ovarian cancer. Cancer Treat Rep 1983;67:997–1000.PubMedGoogle Scholar
  7. 7.
    Misset JL, Bleiberg H, Sutherland W, et al. Oxaliplatin clinical activity: a review. Crit Rev Oncol/Hematol 2000;35 :75–93.CrossRefGoogle Scholar
  8. 8.
    O’Dwyer PJ, Stevenson JP, Johnson SW. Clinical pharmacokinetics and administration of established platinum drugs. Drugs 2000;59:19–27.CrossRefGoogle Scholar
  9. 9.
    Jassem J. Chemotherapy of advanced non-small cell lung cancer. Ann Oncol 1999;10:S77–S82.PubMedCrossRefGoogle Scholar
  10. 10.
    Cortes-Funes H. New treatment approaches for lung cancer and impact on survival. Semin Oncol 29(Suppl 8):2002;26–29.CrossRefGoogle Scholar
  11. 11.
    Huisman C, Postmus PE, Giaccone G, et al. Second-line chemotherapy and its evaluation in small cell lung cancer. Cancer Treat Rev 1999;25:199–206.PubMedCrossRefGoogle Scholar
  12. 12.
    Thigpen T. Second-line Therapy for Ovarian Carcinoma: General Concepts. American Society of Clinical Oncology 1999 American Society of Clinical Oncology: Atlanta, GA, 1999.Google Scholar
  13. 13.
    Berek JS, Bertelsen K, du Bois A, et al. Advanced epithelial ovarian cancer : 1998 concensus statements. Ann Oncol 1999;10(Suppl 1):87–92.PubMedCrossRefGoogle Scholar
  14. 14.
    McGuire WP, Ozols RF. Chemotherapy of advanced ovarian cancer. Semin Oncol 1998;25:340–348.PubMedGoogle Scholar
  15. 15.
    Pendyala L, Creaven P. In vitro cyctotoxcity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res 1993;53:5970–5976.PubMedGoogle Scholar
  16. 16.
    Raymond E, Lawrence R, Izbicka E, et al. Activity of oxaliplatin against humon tumor colonyforming units. Clin Cancer Res 1998;4:1021–1029.PubMedGoogle Scholar
  17. 17.
    Chollet P, Bensmaine A, Brienza A, et al. Single agent activity of oxaliplatin in heavily pretreated advanced epithetial ovarian cancer. Ann Oncol 1996;7:1065–1070.PubMedCrossRefGoogle Scholar
  18. 18.
    Bougnoux P, Dieras V, Petit T, et al. A multicenter phase II study of oxaliplatin (OXA) as a single agent in platinum (PT) and/or taxane (TX) pretreated advanced ovarian cancer (AOC) final results. Proc Am Soc Clin Oncol 1999;18:368a (abstract).Google Scholar
  19. 19.
    Piccart MJ, Green JA, Lacave AJ, et al., Oxaliplatin or paxlitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. J Clin Oncol 2000;18:1193–1202.PubMedGoogle Scholar
  20. 20.
    Harrap KR. Initiatives with platinum and quinazoline-based antitumor molecules. Fourteenth Bruce F. Cain Memorial Award Lecture. Cancer Res 1995;55:2761–2768.PubMedGoogle Scholar
  21. 21.
    Holford J, Sharp SY, Murrer BA, et al. In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. Br J Cancer 1998;77:366–373.PubMedCrossRefGoogle Scholar
  22. 22.
    Holford J, Beale PJ, Boxall FE, et al. Mechanisms of drug resistance to the platinum complex ZD0473 in ovarian cancer cell lines. Eur J Cancer 2000;36:1984–1990.PubMedCrossRefGoogle Scholar
  23. 23.
    Guminski AD, Harnett PR, deFazio A. Scientists and clinicians test their metal-back to the future with platinum compounds. Lancet Oncol 2002;3:312–318.PubMedCrossRefGoogle Scholar
  24. 24.
    Lautier D, Canitrot Y, Deeley RG, et al. Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochem Pharmacol 1996;52:967–977.PubMedCrossRefGoogle Scholar
  25. 25.
    Godwin AK. Meister A, O’Dwyer PJ, et al. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked glutathione synthesis. Proc Natl Acad Sci USA 1992;89:3030–3074.CrossRefGoogle Scholar
  26. 26.
    Wafik S, El-Deiry MD. Role of oncogenes in resistance and killing by cancer therapeutic agents. Curr Opin Oncol 1997;9:79–87.CrossRefGoogle Scholar
  27. 27.
    Leyland-Jones B, Kelland LR, Harrap KR, et al.Genomic imbalances associated with acquired resistance to platinum analogues. Am J Pathol 1999;155:77–84.CrossRefGoogle Scholar
  28. 28.
    Yu Q, Hiorns LR, Bradshaw TD, et al.Profiling gene expression of 2-(4-aminophenyl)benzothiazole-resistant MCF7 cells using cDNA microarray. Submitted.Google Scholar
  29. 29.
    MacGregor PF, Squire JAApplication of microarrays to the analysis of gene expression in cancer. Clin Chem 2002;48:1170–1177.PubMedGoogle Scholar
  30. 30.
    Golub TR, Slonim DK, Tamayo P, Huard C, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999;286:531–537.PubMedCrossRefGoogle Scholar
  31. 31.
    Su AI, Welsh JB, Sapinoso LM, et al. Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res 2001;61:7388–7393.PubMedGoogle Scholar
  32. 32.
    Perou CM, S∅rtie T, Eisen MB, et al.Molecular portraits of human breast tumours. Nature 2000;406:747–752.PubMedCrossRefGoogle Scholar
  33. 33.
    S∅rtie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98:10869–10874.PubMedCrossRefGoogle Scholar
  34. 34.
    Sotiriou C, Powles TJ, Dowsett M, Jazaeri AA, et al. Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res 2002,4:R3.CrossRefGoogle Scholar
  35. 35.
    van’t Veer, LJ, Dai H, van de Vijver MJ, et al.Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415(6871):484–485.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2004

Authors and Affiliations

  • Brian Leyland-Jones

There are no affiliations available

Personalised recommendations